Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 14,058 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 14,058 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.26, for a total transaction of $369,163.08. Following the sale, the insider owned 76,140 shares in the company, valued at approximately $1,999,436.40. This represents a 15.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

David Malcom Rodman also recently made the following trade(s):

• On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.37, for a total transaction of $173,744.76.
• On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.84, for a total value of $58,269.64.
• On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total value of $11,505.03.
• On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $28.99, for a total value of $184,057.51.
• On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.44, for a total value of $385,669.20.
• On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $30.21, for a total value of $65,585.91.
• On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.10, for a total transaction of $13,353.60.
• On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.61, for a total transaction of $370,677.87.
• On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.75, for a total transaction of $252,469.75.
• On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.32, for a total transaction of $205,167.36.

Mineralys Therapeutics Trading Down 1.8%

Shares of Mineralys Therapeutics stock opened at $25.73 on Tuesday. Mineralys Therapeutics, Inc. has a twelve month low of $10.44 and a twelve month high of $47.65. The firm has a market capitalization of $2.12 billion, a PE ratio of -10.86 and a beta of 0.57. The firm’s 50-day moving average price is $30.25 and its 200 day moving average price is $35.73.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17. On average, sell-side analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Institutional Trading of Mineralys Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd raised its position in shares of Mineralys Therapeutics by 3,439.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,823 shares of the company’s stock valued at $139,000 after buying an additional 3,715 shares during the period. Seven Fleet Capital Management LP acquired a new stake in Mineralys Therapeutics during the fourth quarter worth $553,000. XTX Topco Ltd raised its position in Mineralys Therapeutics by 291.1% in the fourth quarter. XTX Topco Ltd now owns 73,678 shares of the company’s stock valued at $2,674,000 after purchasing an additional 54,838 shares during the period. Ikarian Capital LLC purchased a new stake in Mineralys Therapeutics in the fourth quarter valued at $7,258,000. Finally, Sphera Funds Management LTD. lifted its stake in shares of Mineralys Therapeutics by 104.2% in the 4th quarter. Sphera Funds Management LTD. now owns 449,003 shares of the company’s stock valued at $16,294,000 after purchasing an additional 229,093 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on MLYS shares. Jefferies Financial Group reiterated a “hold” rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen upgraded Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday. HC Wainwright set a $56.00 price objective on Mineralys Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Finally, Bank of America upped their target price on Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a report on Friday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $49.14.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.